StockNews.AI
LEXX
StockNews.AI
217 days

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

1. Oral DehydraTECH-tirzepatide showed 47% fewer adverse events than injected Zepbound. 2. Glycemic control and insulin secretion were comparable between both formulations.

2m saved
Insight
Article

FAQ

Why Bullish?

The reduced adverse events indicate a promising alternative, potentially boosting LEXX's market appeal.

How important is it?

The study's positive results may directly enhance LEXX's valuation and investor interest.

Why Long Term?

Successful absorption and efficacy can lead to increased adoption over time, similar to competitors in the drug delivery sector.

Related Companies

ZEPLEXXW
Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®. The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.

Related News